The injection is commonly used across several critical therapeutic domains, generally targeting symptoms related to systemic imbalance and heightened physiological activity.

The medication is applicable in clinical settings that involve acute or unstable symptom patterns, particularly for conditions characterized by intense, disruptive episodes. This includes immediate hormone replacement for acute adrenocortical insufficiency (adrenal crisis), control in severe allergic reactions like anaphylaxis or asthma crises, and short-term support during acute exacerbations of systemic conditions such as rheumatoid arthritis or ulcerative colitis.

The primary benefit is that it assists with symptomatic relief and supports general well-being during symptomatic phases. It supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.

“Applied in scenarios where additional management of discomfort is required.”

Quick Fact: Relief for Acute Inflammation and Systemic Crisis Hidrocortisona Richet is often used when symptoms intensify and supportive relief is needed, providing support with hormone levels or addressing symptoms related to inflammatory or irritative states.

Regulatory References

1. NIH DailyMed

Hidrocortisona Richet (hydrocortisone) is a topical corticosteroid used to relieve inflammation and itching associated with various skin conditions. While generally safe for short-term use in most adults and children over 10 years old, its use is subject to specific precautions and contraindications.

---

When to Use with Caution or Avoid

Consult a healthcare professional before use if you have any existing medical conditions or are in a sensitive population, as the risk of systemic absorption and side effects increases with prolonged use, application to large surface areas, or use under occlusive dressings.

Population / Condition	Guidance
Children under 10	Use only under the guidance of a doctor or pharmacist.
Pregnancy/Breastfeeding	Consult a doctor. Generally, mild topical corticosteroids are used only when potential benefits outweigh the risks. Wipe off if applied to the breast area before feeding.
Infections	Do not use if the treatment area has an untreated bacterial, fungal, viral (e.g., herpes, chickenpox), or parasitic infection. Corticosteroids can mask or worsen these conditions.
Other Skin Conditions	Do not use for conditions like acne, rosacea, or perioral dermatitis. Avoid application to broken skin or skin ulcers.
Other Areas	Avoid use near the eyes. Avoid long-term use on thin-skinned areas such as the face, armpits, or groin, unless directed by a physician.

Interactions with other medicines and products

The interaction profile for Hydrocortisone is documented by regulatory agencies and focuses on altering the drug's exposure and increasing the risk of specific adverse effects when co-administered with other medicinal products.

Pharmacokinetic Interactions

Hydrocortisone is metabolized by the CYP3A4 enzyme system. This results in formally documented interactions that alter its plasma concentration:

• CYP3A4 Inhibitors (e.g., Ketoconazole) increase Hydrocortisone plasma concentrations by reducing its metabolism, which raises the potential for dose-related effects.
• CYP3A4 Inducers (e.g., Rifampin, Phenytoin) decrease Hydrocortisone plasma concentrations by accelerating its metabolism, which can lead to a loss of the corticosteroid's intended action.

Pharmacodynamic and Procedural Restrictions

Official labeling describes interactions based on combined effects and administration rules:

• Contraindication: Live or Live-Attenuated Vaccines must not be administered during immunosuppressive Hydrocortisone dosing, as this combination is documented to increase the risk of infection and diminish immune response.
• Increased Risk of Hypokalemia: Co-administration with Potassium-Depleting Agents (such as Amphotericin B or diuretics) significantly increases the risk of low potassium due to additive electrolyte effects.
• Gastrointestinal Risk: Concomitant use with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) increases the risk of gastrointestinal ulceration and bleeding.
• Antagonistic Effects: Hydrocortisone can counteract the effects of Antidiabetic Agents by raising blood glucose levels.

Patients with pre-existing conditions like Cirrhosis or Hypothyroidism are documented to experience an enhanced effect of Hydrocortisone due to physiological alteration of drug clearance.

Hidrocortisona, a synthetic glucocorticoid, acts primarily by binding to the cytosolic glucocorticoid receptor (GR). The activated receptor-ligand complex translocates into the nucleus, where it functions as a transcription factor to modulate gene expression.

This genomic mechanism alters the transcription of multiple genes, resulting in the upregulation of anti-inflammatory proteins (such as lipocortin-1) and the downregulation of pro-inflammatory cytokines (including IL-6 and TNF-alpha).

At the cellular level, the compound inhibits the enzymatic activity of phospholipase A2, which consequentially leads to decreased synthesis of prostaglandins and leukotrienes. Furthermore, it acts to inhibit mast cell degranulation and stabilize lysosomal membranes. This mechanism also involves the inhibition of T-lymphocyte proliferation and a reduction in IgE-mediated histamine release from basophils.

Administration and Dosing Guidelines

Hidrocortisona Richet (Hydrocortisone Sodium Succinate for injection) is administered for acute, short-term treatment. Its use is governed by specific instructions for preparation, administration route, and dosage schedule, and it is primarily utilized in a controlled medical setting.

---

Official Administration Protocol

Component	Official Guideline
Route of Administration	Intravenous (I.V.) injection or infusion is preferred in emergencies; Intramuscular (I.M.) injection is also approved.
Reconstitution	The sterile powder must be aseptically reconstituted by adding no more than 2 mL of Sterile Water for Injections or other approved diluent immediately before use.
I.V. Injection Rate	A dose of 100 mg must be administered over a minimum of 30 seconds. Doses of 500 mg or more must be given over a minimum of 10 minutes.

---

Standard Dosing and Schedule

• Adults: The typical initial dose ranges from 100 mg to 500 mg, determined by the severity of the patient's condition.
• Pediatric Patients: Dosing is based on clinical need, and the amount administered should not be less than 25 mg daily. Growth and development require careful observation if therapy is prolonged.
• Frequency: The initial dose may be repeated at intervals of 2, 4, or 6 hours as indicated by the patient's acute needs.
• Duration and Transition: High-dose therapy is generally intended for a limited period, typically not exceeding 48 to 72 hours. The treatment protocol mandates a transition to oral or lower-dose maintenance therapy as soon as the condition stabilizes to prevent adverse effects associated with long-term high-dose use.

Research evidence / Overview of Studies for Hidrocortisona Richet

---

Evidence for Use in Acute Adrenocortical Insufficiency and Hormone Replacement

This section summarizes the foundational studies and clinical consensus guidelines that describe the long-standing use of the injection for immediate steroid replacement and in the context of an adrenal crisis, focusing on the physiological and pharmacokinetic research that underpins its role.

The evidence for this injectable medicine was evaluated in the context of an acute adrenal crisis, derived from historical data and established physiological rationale. Replacement therapy is described as the established approach for addressing essential hormone levels. Research has explored the time required for the active ingredient to reach its measured peak concentration after administration, tracking its absorption and distribution patterns. Findings highlight changes measured in outcomes related to physiological strain or stress, such as blood pressure stabilization.

However, due to the critical nature of this condition, modern randomized controlled trials (RCTs) comparing the injection to placebo are not performed. The foundation of this practice comes from decades of clinical experience and expert consensus reports.

---

Evidence for Use in Acute Exacerbations of Systemic Inflammatory Diseases

This section describes the randomized controlled trials (RCTs) and observational studies that have examined the injection's use during severe, acute inflammatory episodes, including the types of survival and critical care outcomes measured in these study settings.

Research examined the use of systemic corticosteroids in patients experiencing conditions involving periods of heightened symptoms, such as severe respiratory flares and infections leading to shock. Studies explored outcomes related to systemic or functional imbalance, such as patient survival over defined time intervals and the duration of mechanical breathing support. Findings describe patterns related to the length of stay in the Intensive Care Unit (ICU) and the utilization of supporting medications.

Research highlights that findings were mixed and evidence is limited to specific sub-groups within the critically ill population. High patient heterogeneity in the studied groups means that results apply only to the populations studied, and comparative evidence is lacking between this specific injectable formulation and other systemic steroids for all acute inflammatory indications.

Key Studies & References

1. Clinical Practice Guidelines: Adrenal crisis and acute adrenal insufficiency - The Royal Children's Hospital
2. Hydrocortisone sodium succinate (A-HYDROCORT) Pharmacokinetics and Indications - Pfizer Labeling

Storage and Disposal Information

Hydrocortisone, the active ingredient in Hidrocortisona Richet, requires specific handling and storage conditions based on official regulatory labeling to maintain its stability and effectiveness.

Mandatory Storage Conditions

Formulation	Temperature Requirement	Protection Requirement
Oral/Topical/Unreconstituted Powder	Controlled Room Temperature (20^circ to 25 C)	Topical forms must be protected from freezing.

Stability and Handling

Unreconstituted forms should be stored at Controlled Room Temperature. If the product is an injectable powder that requires reconstitution, the resulting solution must be used only if it is clear and must be protected from light. The stability period is limited: the prepared solution must be discarded if not used within 12 hours at room temperature or 24 hours if refrigerated.

Disposal Rules

Strictly follow official guidance for the safe disposal of all medication. Unused, reconstituted injectable solution must be discarded after its specified stability period.